Screener
Xenon Pharmaceuticals XENE Short-Term Investments
Short-Term Investments at other companies
Other financials
Where this comes from
Reported directly by Xenon Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:MarketableSecuritiesCurrent.
The source filing: Xenon Pharmaceuticals’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:31 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-338244
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $119,527 | $199,163 |
| Marketable securities (note 5) | 811,159 | 349,723 |
| Other receivables | 1,629 | 1,371 |
| Prepaid expenses and other current assets | 13,553 | 10,392 |
| Total current assets | 945,868 | 560,649 |
| Marketable securities, long-term (note 5) | 314,411 | 37,152 |
Item 1. Financial Statements
FAQ
- What is Xenon Pharmaceuticals's short-term investments?
- Xenon Pharmaceuticals (XENE) reported short-term investments of $811.16M in Q2 2026.
- How has Xenon Pharmaceuticals's short-term investments changed year-over-year?
- Xenon Pharmaceuticals's short-term investments increased by 130.3% year-over-year, from $352.16M to $811.16M.
- What is the long-term trend for Xenon Pharmaceuticals's short-term investments?
- Over 5 years (2020 to 2025), Xenon Pharmaceuticals's short-term investments has grown at a 21.5% compound annual growth rate (CAGR), from $131.99M to $349.72M.
- What does short-term investments mean?
- Marketable securities and other investments with maturities between three months and one year, providing yield above cash while maintaining liquidity.
Ask your AI about Xenon Pharmaceuticals's short-term investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude